Video

Dr. Advani on EPOCH-R in B Cell Lymphoma

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, details the difference between EPOCH-R and R-CHOP chemotherapy.

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, details the difference between EPOCH-R and R-CHOP chemotherapy.

Dose-adjusted EPOCH-R is an infusion chemotherapy that uses similar drugs to R-CHOP. In preliminary data, patients overcame poor prognostic significance of Bcl-2 overexpression.

While the results of upcoming trials will give more information, Advani says, dose-adjusted EPOCH-R has become the standard of care in patients with primary mediastinal B-cell lymphoma. In this disease, treatment with R-CHOP usually requires radiotherapy as well but with EPOCH-R alone, cure rates are well above 90% and no radiotherapy is needed.

Related Videos
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Andrew Davis, MD
Hannah Choe, MD, an expert on GVHD